Bamco Inc. NY Purchases 228,977 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Bamco Inc. NY raised its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 29.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,006,129 shares of the company's stock after purchasing an additional 228,977 shares during the period. Bamco Inc. NY owned approximately 1.72% of Inari Medical worth $41,493,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock worth $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock worth $46,000 after buying an additional 435 shares in the last quarter. KBC Group NV boosted its holdings in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. grew its position in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after purchasing an additional 522 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company's stock worth $99,000 after purchasing an additional 926 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NARI has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a "buy" rating and a $68.00 price objective for the company. Robert W. Baird lifted their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a research note on Tuesday, October 29th. Stifel Nicolaus assumed coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price target on the stock. Leerink Partnrs upgraded Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Finally, Piper Sandler lifted their target price on Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a research report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $58.89.

Insider Buying and Selling at Inari Medical

In related news, CFO Mitch C. Hill sold 3,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at $8,105,348. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William Hoffman sold 40,000 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the transaction, the director now directly owns 643,296 shares in the company, valued at $29,482,255.68. This trade represents a 5.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 186,000 shares of company stock valued at $8,990,990. 10.60% of the stock is currently owned by company insiders.

Inari Medical Price Performance

NARI stock traded down $1.29 during midday trading on Tuesday, hitting $50.83. The stock had a trading volume of 124,157 shares, compared to its average volume of 976,279. The business has a fifty day moving average price of $46.48 and a two-hundred day moving average price of $47.58. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.